A new study shows that people with prurigo nodularis treated with nemolizumab (sold as Nemluvio) experienced sustained relief from intense itch and skin lesions for up to two years. The treatment was also well tolerated, with no new safety concerns reported.
Approved by the U.S. Food and Drug Administration in 2024, nemolizumab is the first and only biologic therapy approved to treat prurigo nodularis, a chronic skin condition marked by intensely itchy, thick nodules. The drug is a monoclonal antibody that targets interleukin (IL)-31, a molecule that triggers itch and skin inflammation. By blocking IL-31 signals, nemolizumab helps reduce both itch and skin damage.
Nemolizumab is given as a subcutaneous (under the skin) injection.
In an ongoing clinical trial, researchers followed more than 500 people with moderate to severe prurigo nodularis. After 100 weeks of treatment:
Researchers noted that nemolizumab continued to be safe and effective over time, and no new side effects were seen. According to the drug’s prescribing information, the most common side effects include headache and types of eczema.
Prurigo nodularis is often difficult to manage, with few treatment options available. These new findings offer hope that nemolizumab may help provide lasting relief from some of the most disruptive symptoms — like persistent itching and visible nodules.
If you’re living with prurigo nodularis and aren’t finding relief with your current treatment, speak with your dermatologist about alternatives. Together, you can create a plan that meets your specific treatment goals.
Learn about nine treatment options available for prurigo nodularis.
On MyPrurigoTeam, people share their experiences with prurigo nodularis, get advice, and find support.
Have you found an effective treatment for prurigo nodularis? Let others know in the comments below.
Get updates directly to your inbox.
Become a member to get even more
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.